JDRF-supported researchers have found that dysfunction of pancreatic beta cells precedes the onset of T1D in a mouse model of the disease. The study is the first direct demonstration that ER stress happens before the onset of T1D in an animal model. These findings help illuminate the earliest stages of T1D, and suggest that alleviating ER stress with drugs or other therapeutics might provide an avenue for slowing progression and onset of disease.
JDRF has partnered with San Diego–based medical company Dexcom, Inc. to support the manufacture of a so-called smart transmitter prototype, which will be available for research purposes before it will be commercially available. The technological advance not only would reduce the number of devices a person would have to wear with an artificial pancreas system, but would also enable wireless connectivity among these devices—an important feature that would give people with T1D the freedom of movement while participating in real-life outpatient studies.
JDRF and the Canadian government are expanding the Adolescent Type 1 Diabetes Cardio-Renal (heart and kidney) Intervention Trial (AdDIT) by adding one additional clinical site in southern Ontario, Canada. The expansion will serve to accelerate the recruitment of adolescents with type 1 diabetes (T1D) and microalbuminuria, a condition in which a protein called albumin leaks into the urine—a sign of early kidney disease and a risk factor for developing heart disease later in life.
In one of the largest studies of its kind, JDRF has partnered with iCo Therapeutics to investigate a potential new drug that could, if successful, broaden treatment options for people living with DME. The Phase II trial, led and coordinated by Johns Hopkins University investigators, is currently recruiting participants. To inquire about participation, please contact Dr. Quan Dong Nguyen or click here.
Taking oral insulin in combination with low-dose anti-CD3 results in long-term reversal of type 1 diabetes in mice whose immune systems specifically attack insulin. The findings, if translated to humans, would help not only to identify people who are most likely to benefit from the therapy, but also to determine whether the therapy is working.
Previous research identified high levels of the enzyme plasma kallikrein in patients with diabetic macular edema, a condition that can cause impaired vision or blindness. JDRF-funded studies by KalVista Pharmaceuticals aim to identify new therapies that will reduce levels of plasma kallikrein and preserve the eyesight of people with T1D.
Consistent with its leadership role in T1D research, JDRF is prioritizing the investigation of biomarkers. We are advancing the knowledge about the direction and needs of research in this critical area, with the goal of providing vital information to reliably measure or predict disease progression in individuals with T1D and to indicate their responsiveness to therapies. Supporting the development of biomarkers for T1D could provide industry with tools to allow for more efficient and attractive incentives to pursue therapies for the disease.
by Thania Benios For people with type 1 diabetes (T1D) awaiting an islet transplant, a single phone call could change their life. The waiting list for these transplants stretches on, and far too often only serendipity propels a patient to the front of the line. These transplanted islets hold the promise of supplying a patient […]
JDRF-funded scientists are conducting new research to create a blood test that may reveal when beta cells are lost during the development of type 1 diabetes (T1D). The test, which is the first of its kind, could be used to identify individuals who have begun to develop T1D, but do not yet have abnormally high […]
The JDRF Artificial Pancreas Project has significantly accelerated progress toward the delivery of the first artificial pancreas (AP) systems to people with diabetes. Research progress has been exceptional with multiple studies in controlled settings demonstrating that AP systems can significantly reduce high and low blood sugar levels automatically. For people with diabetes to realize the […]